Novartis to acquire anti-inflammatory drugmaker IFM Tre in $1.6bn deal
Swiss pharma giant Novartis has agreed to acquire IFM Tre from US biopharma company IFM Therapeutics in a deal worth up to $1.575bn, to add certain immunomodulatory medicines to its portfolio.